Responses of Medical R&D to Changing Economic Incentives: Implications for the Future of Health Care Costs and Quality

David Dranove and Burton A. Weisbrod

IPR working papers from Institute for Policy Resarch at Northwestern University

Abstract: With a growing emphasis on cost containment, health care providers must increasingly consider costs whenever they adopt new technologies. This has implications for the kinds of technologies that medical R&D firms develop. We report the results of a survey of 58 medical R&D firms to determine how, if at all, medical research portfolios are changing. Compared with 1990, we find that medical R&D firms today place a significantly greater emphasis on developing products that will lower costs. At the same time, their emphasis has switched from ³me-too² technologies to more innovative technologies offering the promise of major quality improvement.

References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wop:nwuipr:98-9

Access Statistics for this paper

More papers in IPR working papers from Institute for Policy Resarch at Northwestern University Contact information at EDIRC.
Bibliographic data for series maintained by Thomas Krichel ().